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Leukocyte function-associated molecule 1 (LFA-1) is an integrin that 
plays a major role in the immune system. Recent findings demonstrate 
that LFA-1 has a two-tvay signaling function, mediating cell adhesion and 
stimulating intracellular processes at the same time. Here, Marijke Lub} 
Yvette van Kooyk and Carl Figdor discuss the finside~ouf and routside-in’ 
signaling properties o f LFA-1, as a prototype leukocyte integrin3 in nor­
mal and malignant T  cells. They integrate data into a model that highlights
the role o f the cytoskeleton in the regulation o f LFA-1,
Leukocyte function-associated molecule 1 (LFA-1; 
CDlla/CD18) is similar to other integrins in that it 
comprises an ct and a (3 chain that are noncovalently 
associated1. It is a member of the (32 group of integrins, 
which includes Mac-1 (CDllb/CD18) and pl50,95, 
these being exclusively expressed by leukocytes. Acti­
vation of LFA-1 is a prerequisite for ligand binding2’3 
and, thus far, three ligands of LFA-1 have been iden­
tified: intercellular adhesion molecule 1 (ICAM-1), 
ICAM-2 , and ICAM-3 (Ref. 4). Circulating peripheral 
blood lymphocytes (PBLs) generally express an inactive 
form of LFA-1; this is crucial to maintain homeostasis, 
since constitutively active LFA-1 would cause instanta­
neous aggregation of circulating cells and clogging 
of the vessels. Intracellular signals are generated only 
after activation of a lymphocyte, for instance through 
the T-cell receptor TCR/CD3 complex or by phorbol 
12-myristate 13-acetate (PMA), and these signals cause 
transient activation of LFA-1 (Refs 2,3). This process is 
referred to as ‘inside-out’ signaling (Fig. 1). In addition 
to the TCR/CD3 complex, several other leukocyte sur­
face receptors5 can activate LFA-1 through G proteins 
or protein tyrosine kinases (PTKs). These activate pro­
tein kinase C (PKC) and increase intracellular calcium 
levels ([Ca2+]j) as a result of phospholipase Gy (PLO/)- 
mediated inositol breakdown. Influx of extracellular 
Ca2_f and lipids have also been demonstrated to activate
LFA-1 (Refs 6,7).
Recent findings show that crosslinking of LFA-1 at 
the cell surface by antibodies can induce intracellular 
signals8,9, suggesting that ligand binding can affect cellu­
lar functions such as apoptosis, cytotoxicity, prolifer­
ation, cytokine production and antigen presentation10' 12. 
This is referred to as ‘outside-in’ signaling (Fig. 1). The 
relatively short cytoplasmic tails of leukocyte integrins 
do not contain any known catalytic domains, therefore 
any ligand-induced stimulation of PTKs or inhibition 
of protein tyrosine phosphatases (PTPs) must be in­
direct. Although there is ample precedent for modu­
lation of non-receptor PTKs and PTPs by ligation of 
the TCR/CD3 complex, it is not known which protein- 
protein interactions are responsible for integrin-mediated 
tyrosine phosphorylation13,14. Ligand-induced oligomer­
ization of surface receptors may initiate signaling by 
bringing together catalytic units of PTKs on the cyto­
plasmic tails of receptor subunits or on associated pro­
teins15. Alternatively, oligomerization may organize cyto- 
skeletal complexes that serve as frameworks for the 
association of PTKs. Possible candidate PTKs in leuko­
cytes include p72sy^ , ZAP-70, p56lckj p65fyn and p l25FAK 
(Ref. 16). Indeed, recent information links integrin- 
mediated pl25M  phosphorylation to the Ras/mitogen- 
activated protein kinase (MAPK) signal transduction 
pathway17. Furthermore, dephosphorylation by CD45 
may negatively regulate LFA-1-mediated signaling in 
lymphocytes8,18; although, on thymocytes, CD45 is re­
ported to stimulate LFA-l-mediated adhesion19.
The highly conserved GFFKR motif in the cytoplasmic 
domain of the a chain of integrins seems to play a ma­
jor role in modulating integrin function. The observation 
that the nuclear protein calreticulin, a negative regu­
lator of gene expression, can directly bind to the GFFKR 
region20 suggests that sequestration of calreticulin to the 
cell surface by binding to integrins21 is involved in the 
activation process of integrins, and may disclose a new 
signaling pathway. Furthermore, the observation that 
deletion of this region results in a constitutively active 
form of LFA-1 underscores the importance of this motif 
in LFA-1 function22.
Conformational changes and multimerization of LFA-1
Despite the wealth of information gathered, the pre­
cise mechanism that controls LFA-l-mediated ligand 
binding remains unknown. The expression of integrin 
neo-epitopes upon activation or after ligand binding 
suggests that alterations in the conformation of integ­
rins are important for ligand binding11,23,24. This 
notion is supported by the observation that certain 
monoclonal antibodies raised against LFA-1 have the 
capacity to induce ligand binding rather than inhibit 
LFA-1-TCAM interactions (Table 1). Alterations in the 
conformation of integrins can also be achieved upon 
divalent cation binding, since integrin-mediated adhe­
sion depends on the presence of Mg2+, Ca2'H and Mn2'1' 
(Refs 25-27). Whereas binding of Mn2+ directly acti­
vates LFA-1 by itself, Mg2+ supports LFA-l-mediated 
adhesion only after additional stimuli (e.g. intracellular 
signals or activating antibodies). Although the role of 
Ca2+ has remained obscure, previous observations 
showing that integrins can aggregate at the cell surface28
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Fig. 1. Signaling pathways mediated by leukocyte function- 
associated molecule 1 (LFA-1). Ligation o f the T-cell receptor 
(TCR)/CD3 complex by major histoco?npatibility complex (MHC) 
and peptide results in activation o f LFA-1 through intracellular 
signals (termed ‘inside-out* signaling). Subsequent binding of inter' 
cellular adhesion molecule '1 (ICAM-1) by active LFA-1 results m 
cell adhesion, and generates intracellular signals (termed outside-in’ 
signaling) that affect the functional activity o f  the cell. Molecules 
that are implicated in LFA-l-mediated signaling include: protein 
tyrosine kinase (PTK)S protein tyrosine phosphatase (PTP), 
protein kinase C (PKCJj intracellular calcium levels [Ca2+}[i
intracellular pH and lipid.
T cells27. This finding may explain why activated T cells 
(L16hi) readily bind ligand upon appropriate stimulation, 
whereas resting lymphocytes express less-clustered LFA-1 
(L16l°) and bind ligand less avidly.
The importance of multimerization of integrin re­
ceptors has also been reported by others29, ■ and is 
essential to trigger 'outside-in5 signaling. Indeed, it has 
been convincingly demonstrated that the induction of a 
high-affinity state by deleting the GFFKR motif is not 
sufficient for stable LFA-l-mediated cell adhesion; it 
still requires multimerization of LFA-1 (Ref. 22). Inter­
estingly, divalent cations have been shown to exert dis­
tinct effects on integrin function. Multimerization of 
LFA-1 is exclusively mediated by Ca2+, while Mg2* 
and Mn2+ have no such effect (Ref, 27; Y. van Kooyk 
et a i,  unpublished). These findings demonstrate that 
divalent cations control LFA-l-mediated adhesion by 
two distinct mechanisms (Fig. 2): (1) Mg2+- or Mn2+- 
dependent alterations in the ligand-binding affinity 
of LFA-1; and (2) Ca2+-dependent multimerization of 
LFA-1, which enhances the avidity of LFA-1 ligand inter­
actions. Because of these differences, Mn2+, Mg2+ and 
Ca2+ probably bind to distinct sites on integrins, and 
may have a cooperative effect on ligand binding25-27.
Active and inactive forms of LFA-1
As discussed above, LFA-1 is only transiently acti­
vated after stimulation by agonists (Fig. 1). This holds 
true not only for freshly isolated lymphocytes, but also 
for a number of long-term T-cell cultures (Table 1). 
This observation, and the fact that (32 integrins are 
exclusively expressed by leukocytes, raises the question 
as to how LFA-1 is regulated in non-leukocytic cells, 
which lack leukocyte-specific elements,
When LFA-1 is expressed on non-leukocytic cells, 
distinct phenotypes are observed. Adherent mouse 
L-cell fibroblasts and monkey COS cells abundantly 
express the LI 6 epitope, whereas non-adherent K562 
cells are L16l°. Furthermore, as summarized in Table 1, 
L or COS cells express a constitutively active form of 
LFA-1, whereas K562 cells express a form that is not 
responsive to PMA, suggesting that at least some regu­
latory elements are missing; they can only be stimu­
lated by activating antibodies (Ref. 24; M. Lub et al., 
unpublished). The importance of intracellular signals 
in the regulation of LFA-1 is demonstrated further by 
the finding30’31 that some leukemic T-cell lines (Jurkat, 
CEM) cannot mediate adhesion through LFA-1 after 
stimulation with physiological agonists or PMA (Table 1). 
Interestingly, these leukemic cells are unable to form 
multimers of LFA-1 at the cell surface (L16l°), despite
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significant LFA-1 expression31. Preliminary findings indi­
cate that this phenomenon originates from defective 
signaling pathways rather than from structural defects 
in LFA-1 (Ref. 30; Y. van Kooyk et al., unpublished).
Regulation of LFA-1 ligand binding by the cytoskeleton
Integrins can associate with cytoskeletal components 
(a  actinin, talin), particularly through the (3 chain32,33. 
Hibbs et ¿z/.34 identified a TTT motif in the (3 chain 
that is important for LFA-l-mediated ICAM-1 bind­
ing. However, despite this information, molecular 
mechanisms involved in the association of LFA-1 with 
the cytoskeleton remain largely elusive. According to the 
model proposed in Fig. 3, transient release of LFA-1 
from the cytoskeleton, or cytoskeleton-associated mol­
ecules, modulates the affinity of LFA-1 for its ligand. 
This model has two major advantages. First, the ca­
pacity to couple and uncouple integrins to and from 
cytoskeletal elements provides leukocytes with a mecha­
nism to support cell locomotion. Second, the cyto­
skeleton or associated molecules may act as a repressor, 
and prevent alteration of the affinity state of LFA-1; 
thus, activation of LFA-1 would require uncoupling 
from cytoskeletal elements (de-repression).
In leukocytes, actin polymers assemble into short 
filaments attached to the cytoplasmic face of the mem-
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Fig. 2. Binding o f leukocyte function-associated molecule 1 (LFA-1) to inter­
cellular adhesion molecule 1 (ICAM-1) is regulated by two distinct mecha­
nisms: Mg2-*-dependent alteration in the affinity o f  LFA-1; and Ca1 ^ -depend­
ent multimerization o f LFA-1. Maximal adhesion is observed on cells that 
express LFA-1 in a high-affinity state3 clustered on the ceil surface.
brane35. This membrane-associated actin network con­
fers rigidity to the cell membrane, and may bind and 
stabilize the integrin subunits in quiescent cells (Fig. 3a).
In addition, because of the highly dynamic nature of 
leukocytes, membrane-anchored microfilaments may
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Fig. 3. Model describing the interaction between leukocyte function-associated molecule 1 (LFA-1) and the cytoskeleton. (a) The cell 
cortex (comprising short actin filaments, other cytoskeletal proteins and associated molecules; depicted in yelloiu) stabilizes LFA-1 at 
the surface of quiescent leukocytes and prevents it from becoming active (repressionJ. (b) Intracellular signals released upon ligation 
o f  the T-cell receptor (TCR)/CD3 complex (not shown), and agonist, temporarily relieve constraints on the cytoplasmic domains o f 
LFA-1, permitting the conformational dynamics required for recognition o f intercellular adhesion molecule 1 (1 CAM-1), and exposing 
the conserved GFFKR m otif on the a chain. This results in binding o f an unknown factor (X) (see text for details), (c) Binding of 
ICAM-1 initiates a series o f  post-receptor signaling events -  multimerization o f LFA-1, actin polymerization (depicted in red), and
protein tyrosine kinase activity -  which may result in initiation o f transcription. The TTT motif on the fi chain o f
LFA-1 plays an important role in post-receptor events.
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also directly control integrin function. According to the 
model, intracellular signals from physiological agonists 
(I.e. TCR engagement), or stimulation with PMA, cause 
a temporary dislodgement of LFA-1 from these short 
actin filaments, allowing LFA-1 to adapt to an active 
conformation (Fig. 3b). Evidence in favor of this hy­
pothesis comes from several recent findings. First, en­
hanced motility of ligand-coated gold particles bound 
by integrins is observed upon stimulation with PMA 
(D. Kucik and E. Brown, pers. commun.). Furthermore, 
cytoch alas ins, which inhibit actin polymerization, not 
only increase integrin motility36, but also clearly en­
hance the binding of ligand by Mac-1 on monocytes35. 
Cytochalasin D was also demonstrated to enhance 
LFA-l-mediated adhesion to ICAM-1 of resting lympho­
cytes (M. Lub et aL, unpublished). Similarly, on U937 
cells cultured with PMA, pl50,95-mediated rosetting 
of sheep erythrocytes opsonized with complement factor 
C3bi (EC3bi) could only be observed when these cells 
were treated with cytochalasin D (Ref. 37). Together, 
these findings suggest that enhanced ligand-binding 
affinity of integrins is preceded by a temporary release 
from the cytoskeleton.
The release of LFA-1 from the cytoskeleton or asso­
ciated molecules may expose the GFFKR motif, result­
ing in binding of an unknown factor (X) (Fig. 3b) that 
is similar to calreticulin binding to the GFFKR sequence 
in Pj integrins20. Subsequent ligand binding (Fig. 3c) 
results in receptor multimerization, induction of PTK 
activity and actin polymerization, as well as other post­
receptor binding events. Multimers of LFA-1 would then 
allow firm adhesion to adjacent cells and support func­
tional activity by intracellular signals. Affinity modulation 
of LFA-1 has been shown to be an independent pro­
cess2*2 and precedes focal contact formation (multimers 
of LFA-1). Although the high affinity of LFA-1 is suffi­
cient to bind ligand, strong cell-cell adhesion requires 
post-receptor reorganization of the cytoskeleton (i.e. actin 
polymerization, receptor capping).
PTP-mediated dephosphorylation of cytoskeletal- or 
cytoskeleton-associated proteins would ultimately 
revert LFA-1 into its inactive state8. This inactivation 
does not necessarily lead to an immediate disruption of 
the multimers, which may remain at the cell surface, 
thus favoring rapid binding of (previously) activated 
T cells as compared with naive resting T cells (Table 1). 
Interestingly, cytochalasin treatment of activated T cells 
that express clustered LFA-1 (Fig. 3c) inhibits ligand 
binding (M. Lub et al.3 unpublished), indicating that 
association of LFA-1 with the cytoskeleton of resting 
(Fig. 3a) and activated lymphocytes (Fig. 3c) is distinct. 
These differences between cell types may also explain 
why inhibition of adhesion by cytochalasins has been 
reported38"40.
Concluding remarks
This article has attempted to integrate data on the 
regulation of LFA-l-mediated adhesion as a prototype 
leukocyte integrin. What can be learned from the above 
discussion of recent progress in the integrin field? First, 
measurement of expression levels of integrin molecules 
is only of limited value, since it provides no infor­
mation on the functional status of these molecules.
Second, it is clear that integrins have a two-way signal­
ing function, mediating information from within the 
cell to outside and vice versa. Third, we begin to gain 
some insight as to  the machinery employed by a leuko­
cyte to control integrin-mediated function. At least two 
distinct mechanisms can be distinguished: alteration of 
ligand-binding affinity mediated by structural changes, 
and the multimerization of LFA-1 molecules at the cell 
surface that is required for stable cell adhesion. Highly 
dynamic interactions of the cytoskeleton with LFA-1, 
and tyrosine phosphorylation of its components, prob­
ably controls functional activity. The challenge now is 
to unravel the precise role of each element in the trans­
mission of signals to the cytoskeleton and the nucleus.
Finally, some leukemic T cells exhibit defective forms of 
LFA-1, probably due to inappropriate signaling. It will be 
worthwhile to investigate these cells in more detail, since 
identification of such defects may be instrumental for an 
improved understanding of the regulation of LFA-l-medi­
ated adhesion, and might provide insight into whether 
these defects are related to the progression of leukemia.
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Serum gangliosides as endogenous 
immunomodulators
Lev D. Bergelson
Gangliosides suppress various immune activities in vitro and in vivo. 
Their level is significantly elevated in tumors and atherosclerotic aorta tis­
sue, as well as in the sera o f patients with tumors or atherosclerosis. Here 3 
Lev Bergelson suggests that ganglioside-induced immunomodulation might 
be involved in atherogenesis and carcinogenesis, and describes a hypothe­
sis that cites gangliosides as a factor interfering with the clearance o f low-
density lipoproteins (LDLs) and promoting the formation
o f atherosclerotic plaques.
Gangliosides are a family of acidic glycosphingolipids 
present in all eukaryotic cells. Their molecular struc­
ture comprises a hydrophobic tail (ceramide) and a 
hydrophilic (oligosaccharide) moiety containing one 
or several residues of sialic acid (Fig. 1). Gangliosides 
exhibit receptor or co-receptor functions for many bio­
active agents, including cytokines, hormones, toxins 
and viruses, and are considered to be involved in cell 
differentiation and morphogenesis, as well as in cellu­
lar recognition, cell-cell interaction and growth regu­
lation. Many gangliosides show antigenic properties 
(e.g. blood group, embryonic and tumor antigens) 
(reviewed in Refs 1,2).
The majority of gangliosides are situated in the 
outer leaflet of the cell membrane, such that the sugar 
moiety protrudes into the extracellular space. However, 
gangliosides also occur in non-cell-associated forms in 
blood plasma and other body fluids, and there is a 
constant exchange between cell-associated and non-cell- 
associated gangliosides. Moreover, some fast-growing 
cells actively release gangliosides into the circulation. 
Indeed, the shedding of gangliosides from some tumor
cells may occur at strikingly high rates, and appears to 
correlate with tumorigenicity and cell density3-6. Since 
exogenous gangliosides are able to associate with cells 
via different mechanisms, changes in the ganglioside 
profile of one cell type (‘ganglioside donors5) may re­
sult in modulation of the surface properties, enzymatic 
activities and function of another cell type (‘ganglio­
side acceptors’). In this sense, serum gangliosides may 
be considered as a form of soluble cytokine. This article 
will discuss the origin, composition and status of cir­
culating gangliosides, the interaction of gangliosides 
with cells of the immune system and the immunological 
consequences of this phenomenon.
The origin and status of circulating gangliosides
The presence of gangliosides in serum was discovered 
as early as 1963 (Ref. 7). Although the concentrations of 
gangliosides reported in human serum vary, it is now 
established that elevated levels occur in some patho­
logical conditions such as cancer and atherosclerosis 
(reviewed in Refs 8,9). The potential significance of 
these elevations will be discussed below.
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